Viral Hepatitis C - euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary 2005 full year

euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Intercell announces preliminary 2005 full year
vwd.de - Mar 05 10:43 PM
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.Save to My Web

Novelos Therapeutics Announces $12.9 Million Private Placement
[Press Release] Business Wire via Yahoo! Finance - Mar 02 7:33 AM
NEWTON, Mass.----March 2, 2006--Novelos Therapeutics, Inc. , a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has entered into definitive securities purchase agreements with institutional investors to raise $12.86 million in gross proceeds through the sale of shares of its common stock and warrants.Save to My Web

ViRexx Presents Hepatitis C Chimigen'TM' Technology at Baculovirus & Insect Cell Culture Annual Meeting
[Press Release] Business Wire via Yahoo! Finance - Feb 22 5:00 AM
EDMONTON, Alberta----Feb. 22, 2006--ViRexx Medical Corp. , a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that Rajan George, Ph.D., Vice President Research and Development of ViRexx, made a presentation about the Company's Chimigen technology for hepatitis C at the 9th Annual Meeting of the Save to My Web

Human Genome Sciences Reports Positive Interim Results of Phase 2 Trial of Albuferon(TM) In Combination With Ribavirin
[Press Release] PR Newswire via Yahoo! Finance - Mar 14 5:01 AM
Human Genome Sciences, Inc. today reported the interim results of a Phase 2 clinical trial to evaluate the safety, tolerability and efficacy of Albuferon in combination with ribavirin in patients with chronic hepatitis C who failed to respond to previous interferon alpha-based treatment regimens.Save to My Web